CN103638563A - Biological liquid of biological albumin glue - Google Patents
Biological liquid of biological albumin glue Download PDFInfo
- Publication number
- CN103638563A CN103638563A CN201310619137.0A CN201310619137A CN103638563A CN 103638563 A CN103638563 A CN 103638563A CN 201310619137 A CN201310619137 A CN 201310619137A CN 103638563 A CN103638563 A CN 103638563A
- Authority
- CN
- China
- Prior art keywords
- biological
- parts
- chitosan
- water
- albumin glue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses biological liquid of biological albumin glue, which comprises the following components in parts by weight: 90-100 parts of sodium alginate, 80-110 parts of chitosan, 5-100 parts of edible starch, 5-100 parts of Kabo and 1,000-1,500 parts of water. By use of the organisms with functions of clearing heat and removing toxin, excreting water and diminishing swelling, stopping bleeding, promoting healing and preventing adhesion and by being matched with some biological formulas, the biological liquid disclosed by the invention can realize the functions of sterilizing, quickly stopping bleeding, promoting healing, preventing adhesion and diminishing inflammation, and realizes perfect curative effects on stopping bleeding and promoting healing after surgical treatment using biological albumin glue.
Description
Technical field
The present invention relates to biological field, especially a kind of biological fibrin glue biological fluid.
Background technology
The problem that Fibrin Glue exists, donor sources as different in albumin glue, composition source, the simplification of application and the selection of effectiveness, hemostatic function limitation, mechanical strength and fibrinolytic inhibitor etc.The blood plasma donor that the Fibrin Glue that used is clinically prepared by it can be divided into business pooled plasma type and single donator type.Using is at present business pooled plasma type more widely, and reason is that mixed type albumin glue has better mechanics, biology and rheological property.The composition source of albumin glue has two latencies here, and they are all relevant with use animal originality material, are mainly thrombin of beef and aprotinin.
Summary of the invention
The invention provides the biological fluid of biological fibrin glue that a kind ofly there is good antiinflammatory, hemostasis, promotion healing, prevents the effect of adhesion and sterilization.
The present invention is achieved by the following technical solutions: a kind of biological fluid of biological fibrin glue, it comprises the composition of following parts by weight: sodium alginate 90-100 part, chitosan 80-110 part, food starch 5-100 part, card ripple 5-100 part, water 1000-1500 part.
Preferably, it comprises the composition of following parts by weight: 95 parts of sodium alginates, 100 parts of chitosans, 50 parts of food starchs, 30 parts, ripple of card, 1200 parts, water.
The preparation method of the biological fluid of above-mentioned biological fibrin glue, is characterized in that, takes by weight ratio each components dissolved in water, and 70-90 degree stirs 20-40 minute, packs after cooling.
Advantage of the present invention is: coordinate and utilize heat-clearing and toxic substances removing, inducing diuresis to remove edema and have hemostasis, promotion to heal, prevent the biology of adhesion, and coordinate some biological formulas, can realize sterilization, have hemostasis, promotion to heal, prevent the effect of adhesion and antiinflammatory fast, have hemostasis, promote healing, prevent that the functions such as adhesion and biological fibrin glue have good curative effect.
The specific embodiment
The biological fluid of biological fibrin glue of the present invention, it comprises the composition of following parts by weight: sodium alginate 90-100 part, chitosan 80-110 part, food starch 5-100 part, card ripple 5-100 part, water 1000-1500 part.
Preferably, it comprises the composition of following parts by weight: 95 parts of sodium alginates, 100 parts of chitosans, 50 parts of food starchs, 30 parts, ripple of card, 1200 parts, water.
The preparation method of the biological fluid of above-mentioned biological fibrin glue, takes each components dissolved by weight ratio in water, and 70-90 degree stirs 20-40 minute, packs after cooling.
Sodium alginate has another name called sodium alginate, seaweed gel, Algin, alginate, is the natural polysaccharide carbohydrate extracting in Thallus Laminariae (Thallus Eckloniae).Be widely used in the products such as food, medicine, weaving, printing and dyeing, papermaking, daily-use chemical industry, as uses such as thickening agent, emulsifying agent, stabilizing agent, binding agent, sizing agents.Since the eighties, sodium alginate obtains new expansion aspect food applications.Sodium alginate is not only a kind of safe food additive, and can be used as the base material of bionic foods or remedy diet, because it is actually a kind of native cellulose, can slow down the absorption of fat sugar and cholate, there is the effect that reduces triglyceride and blood glucose in serum cholesterol, blood, can prophylaxis of hypertension, the modern disease such as diabetes, obesity.It can suppress poisonous metal as the accumulation in vivo such as strontium, cadmium, lead, exactly because these important function of sodium alginate are valued by the people day by day at home and abroad in intestinal.Japanese calls " life prolonging food " the food that is rich in sodium alginate, and American is called " marvellous food additive ".Purposes: stabilizing agent, thickening agent, make artificial semipermeable membrane, mordant.Biochemical level is for fixed cell, enzyme; As sodium alginate method immobilized glutamate decarboxylase.
Chitosan (chitosan) is that the chitin (chitin) extensively being existed by nature obtains through deacetylation, chemical name is Chitosan (1-4)-2-amino-B-D glucose, from 1859, first Frenchman Rouget obtains after chitosan, biological functionality and the compatibility of this natural polymer, blood compatibility, safety, the premium properties such as microbic resolvability are by all trades and professions extensive concern, at medicine, food, chemical industry, cosmetics, water treatment, METAL EXTRACTION and recovery, the applied research of the numerous areas such as biochemistry and biomedical engineering has been obtained major progress.For patient, chitosan blood fat reducing, the existing research report of hypoglycemic effect.Under given conditions; the chemical reactions such as chitosan can be hydrolyzed, alkylation, acyl group, carboxy methylation, sulfonation, nitrated, halogenation, oxidation, reduction, condensation and complexation; can generate the various chitosan derivatives with different performance, thereby expand the range of application of chitosan.
Its physiologically active: control cholesterol, Antibacterial activity, prevention and control hypertension, absorption and excretion heavy metal and there is immune effect.
Chitosan has higher protein adsorption ability; Under the effect of digestive enzyme (lysozyme lysozyme, kitinase), chitosan tool degradability; Chitosan is easy to be processed into line, is applicable to making the medical material of wire or lamellar; Chitosan has affinity and dissolubility, is applicable to produce each analog derivative; Chitosan has higher chemism; The retentiveness of chitosan is high; In serum, the easy degraded and absorbed of chitosan; Chitosan has higher biological degradability; Chitosan shows the effect that selectively highly suppresses Streptococcus oralis growth, does not affect the growth of other beneficial bacterias simultaneously.
Chitosan is in medical application: promote blood coagulation and wound healing, as the sustained-release matrix of medicine, for artificial tissue and organ, there is immunoregulatory activity.
Starch: can be regarded as the high polymer pharmaceutic adjuvant of glucose, filler and disintegrating agent etc.Be used as disintegrating agent (Disintegrants): disintegrating agent is to make tablet in gastro-intestinal Fluid, split rapidly the material that is broken into fine particle, except slow (control) releases the tablet of sheet and some specific use, in general tablet, all should add disintegrating agent.Because they have very strong water swellability, can disintegrate the adhesion of tablet, make tablet split and be broken into many tiny granules from a whole tablet, realize the disintegrate of tablet, so be extremely conducive to dissolving and the absorption of principal agent in tablet.Starch is a kind of the most classical disintegrating agent, water content is below 8%, water absorption is strong and have certain dilatancy, be applicable to the tablet of water-insoluble or microsolubility medicine, but the disintegration to soluble drug is poor, this is to produce concentration difference because soluble drug is met water dissolution, makes the difficult inside that penetrates into tablet by solution aspect of water of tablet outside, has hindered the imbibition of tablet internal starch.
Embodiment 1
Take by weight ratio each component: sodium alginate 95g, chitosan 100g, food starch 50g, card ripple 30g, be dissolved in 1200g water, 80 degree stir 20 minutes, pack after cooling.
The performance of product, can draw by following several groups of test datas:
The commercially available constituent of table 1
Table 2 Fibrin Glue and thrombin bleeding stopping period comparison (s)
The comparison of the postoperative section healing state of table 3
Table 4 Fibrin Glue and thrombin bleeding stopping period comparison (s)
Biological fibrin glue of the present invention is identical with original bioresorbable albumin glue, the bioprotein collagen that employing absorbs is completely made, have and the identical biological activity of bioresorbable albumin glue, so also there is the advantage of protozoa absorbability albumin glue, as without antibacterial endomycin, apyrogeneity, virus-free, have no side effect, can be absorbed completely by human body, therefore, while filling wound for biological fibrin glue, can be stayed in human body and needn't be taken out, avoid patient's secondary in by rescue and therapeutic process to bear affliction.And due to albumin glue of the present invention, to be albumen glueballs, the albumin glue of all size aqueous; Therefore, the easy operating during wound of filling all size, shape, filling speed is fast, and particularly, for the open wound of area, its advantage is more obvious.Can in 30 seconds, impel platelet to form rapidly tampon, reach the effect of hemostasis; Bioprotein collagen wherein, can divide a word with a hyphen at the end of a line by inductive factor, is conducive to the regeneration of damaged tissues, impels the healing of wound, and in the agglutination of wound, is progressively absorbed by the body, so albumin glue of the present invention is applicable to the various wound hemostasis of clinical departments; The human tissue injury causing as various operations or wound; The first aid hemostasis of the situations such as daily wound, athletic injury, accidental wound, war wound or for impelling the nursing of wound healing.Because this albumin glue had both had definite shape, its shape ability is very strong again, therefore, direct filling wound when first aid, do not need to its reduce, the pretreatment such as molding.
The main clinical application of table 5FS
Above-described embodiment is only for illustrating technological thought of the present invention and feature, its object is to make those skilled in the art can understand content of the present invention and implement according to this, can not only with the present embodiment, limit the scope of the claims of the present invention, be equal variation or the modification that all disclosed spirit is done, still drop in the scope of the claims of the present invention.
Claims (3)
1. a biological fluid for biological fibrin glue, is characterized in that, it comprises the composition of following parts by weight: sodium alginate 90-100 part, chitosan 80-110 part, food starch 5-100 part, card ripple 5-100 part, water 1000-1500 part.
2. the biological fluid of biological fibrin glue according to claim 1, is characterized in that, it comprises the composition of following parts by weight: 95 parts of sodium alginates, 100 parts of chitosans, 50 parts of food starchs, 30 parts, ripple of card, 1200 parts, water.
3. a preparation method for the biological fluid of biological fibrin glue as claimed in claim 1, is characterized in that, takes by weight ratio each components dissolved in water, and 70-90 degree stirs 20-40 minute, packs after cooling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310619137.0A CN103638563B (en) | 2013-11-28 | 2013-11-28 | A kind of biological fluid of biological fibrin glue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310619137.0A CN103638563B (en) | 2013-11-28 | 2013-11-28 | A kind of biological fluid of biological fibrin glue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103638563A true CN103638563A (en) | 2014-03-19 |
| CN103638563B CN103638563B (en) | 2015-09-02 |
Family
ID=50243932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310619137.0A Expired - Fee Related CN103638563B (en) | 2013-11-28 | 2013-11-28 | A kind of biological fluid of biological fibrin glue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103638563B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106982766A (en) * | 2017-04-01 | 2017-07-28 | 浙江海洋大学 | A kind of method for predicting laying season of portunus trituberculatus |
| CN107308489A (en) * | 2017-05-17 | 2017-11-03 | 广西品位生物科技有限公司 | A kind of biological fluids of biogum |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1435263A (en) * | 2003-03-05 | 2003-08-13 | 成都拓泰医药科技开发有限公司 | Hematostatic gel |
| CN1539514A (en) * | 2003-11-03 | 2004-10-27 | 刘永庆 | Method for preparing multifunctional biological repair material |
| CN101524543A (en) * | 2008-03-07 | 2009-09-09 | 大连永兴生物医药孵化器有限公司 | Hemostatic gel film agent |
| CN101716366A (en) * | 2009-12-17 | 2010-06-02 | 天津大学 | Biocolloid hemostatic prepared by aldehyde-modified sodium alginate and amine-modified gelatine |
| WO2013062994A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating full thickness burn injuries |
-
2013
- 2013-11-28 CN CN201310619137.0A patent/CN103638563B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1435263A (en) * | 2003-03-05 | 2003-08-13 | 成都拓泰医药科技开发有限公司 | Hematostatic gel |
| CN1539514A (en) * | 2003-11-03 | 2004-10-27 | 刘永庆 | Method for preparing multifunctional biological repair material |
| CN101524543A (en) * | 2008-03-07 | 2009-09-09 | 大连永兴生物医药孵化器有限公司 | Hemostatic gel film agent |
| CN101716366A (en) * | 2009-12-17 | 2010-06-02 | 天津大学 | Biocolloid hemostatic prepared by aldehyde-modified sodium alginate and amine-modified gelatine |
| WO2013062994A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating full thickness burn injuries |
Non-Patent Citations (2)
| Title |
|---|
| 田青等: "医用生物蛋白胶的临床应用", 《山西医科大学学报》 * |
| 薛承斌等: "凝胶剂的临床应用研究进展", 《中华医学实践杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106982766A (en) * | 2017-04-01 | 2017-07-28 | 浙江海洋大学 | A kind of method for predicting laying season of portunus trituberculatus |
| CN106982766B (en) * | 2017-04-01 | 2020-12-18 | 浙江海洋大学 | Method for predicting egg laying period of portunus trituberculatus |
| CN107308489A (en) * | 2017-05-17 | 2017-11-03 | 广西品位生物科技有限公司 | A kind of biological fluids of biogum |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103638563B (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Preparation and evaluation of chitosan/alginate porous microspheres/Bletilla striata polysaccharide composite hemostatic sponges | |
| Neuffer et al. | Hemostatic dressings for the first responder: a review | |
| Bilgili et al. | Hemostatic efficacy of Ankaferd Blood Stopper® in a swine bleeding model | |
| Li et al. | Preparation and the hemostatic property study of porous gelatin microspheres both in vitro and in vivo | |
| KR101062068B1 (en) | Anti-adhesion Composition | |
| CN101584876B (en) | Medical compound micropore polysaccharide and application thereof | |
| RU2682717C2 (en) | Degradable haemostat composition | |
| CN105770976B (en) | Dodecyl chitosan is preparing the application in bleeding-stopping dressing | |
| Dowling et al. | Determination of efficacy of a novel alginate dressing in a lethal arterial injury model in swine | |
| CN107243086A (en) | A kind of absorbable compound hemostatic powder and preparation method thereof | |
| Chaturvedi et al. | Hydrophobically modified chitosan gauze: a novel topical hemostat | |
| CN101927027A (en) | Chitosan/carboxymethyl chitosan rapid hemostatic sponge and preparation method thereof | |
| CN103800278B (en) | The application of hyaluronic acid associating polidocanol in preparation treatment venous malformation foam sclerosis medicine | |
| CN103638563B (en) | A kind of biological fluid of biological fibrin glue | |
| EP3359206A1 (en) | Biocompatible carboxymethylcellulose matrix (bcm) for hemostasis, tissue barrier wound healing, and cosmetology | |
| CN109589446A (en) | A kind of absorbable biological hemostatic material and preparation method thereof | |
| CN104874011A (en) | Hemostatic and preparation method and application thereof | |
| CN110755674B (en) | Hemostatic powder and preparation method thereof | |
| CN107412840A (en) | It is a kind of that there is the hemostatic composition for stablizing drug effect | |
| CN105477679A (en) | Polysaccharide crosslinking based quick chitosan hemostatic cotton | |
| CN105412977A (en) | Chitosan wound dressing | |
| CN106822986B (en) | A kind of preparation method of the porous ball hemostatic material of chitosan-agar oligosaccharide | |
| CN107715167A (en) | Chitosan-based hemostatic paste and preparation method as bone wax substitute | |
| CN105727345A (en) | Absorbable hemostasis membrane material and preparation method thereof | |
| WO2017060821A1 (en) | Hemostatic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160427 Address after: 100000 Beijing city Chaoyang District Lu Village Shibalidian Township No. 23 A District No. 232 Patentee after: Beijing Tak Lung Biotechnology Co., Ltd. Address before: 301500, Tianjin County, Ninghe County, West Village, 500 meters north side of the village outside Patentee before: TIANJIN DETAIRAN BIO-PHARMACEUTICAL CO., LTD. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 Termination date: 20161128 |